Dry Eye – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of dry eye disease (DED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of DED for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets in this report.
Clarivate Epidemiology’s DED forecast will answer the following questions:
- Of all people with DED, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with DED, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DED over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts the following DED patient populations:
- Total prevalent cases of DED.
- Diagnosed prevalent cases of DED.
- Diagnosed prevalent cases of mild DED.
- Diagnosed prevalent cases of moderate DED.
- Diagnosed prevalent cases of severe DED.
- Diagnosed prevalent cases of drug-treated DED.
Table of contents
- Dry Eye - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of dry eye disease)
- Total prevalent cases of dry eye disease
- Diagnosed prevalent cases of dry eye disease
- Diagnosed prevalent cases of dry eye disease by severity
- Drug-treated prevalent cases of dry eye disease
- Risk / protective factors applied to disease forecast models
- Reference Materials
Prashant Kumar, M.P.H., Epidemiologist. Prior to joining the company, he coordinated various public health projects focused on tuberculosis, COVID, and malnutrition. He also has experience working in the health insurance domain in India, where he was involved in claims data analytics and stakeholder management. He holds an M.P.H specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.